Patent ID: 9090692
Filing Date: 2015-07-28
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof to a subject in need thereof, wherein the monoclonal antibody or the antigen binding fragment of the monoclonal antibody directly binds one or more amino acid sequences selected from the group consisting of: (a) amino acid residues 21 to 328 of the amino acid sequence of SEQ ID NO: 2; (b) amino acid residues 1 to 260 of the amino acid sequence of SEQ ID NO: 2; (c) amino acid residues 21 to 260 of the amino acid sequence of SEQ ID NO: 2; (d) amino acid residues 21 to 341 of the amino acid sequence of SEQ ID NO: 4; (e) amino acid residues 1 to 258 of the amino acid sequence of SEQ ID NO: 4; and (f) amino acid residues 21 to 258 of the amino acid sequence of SEQ ID NO: 4, where (a)-(f) are in one or more polypeptides; wherein the monoclonal antibody or the antigen binding fragment of the monoclonal antibody contains the same Complementarity Determining Regions (CDRs) as a monoclonal antibody produced by a hybridoma selected from the group consisting of hybridoma #32A1 (FERM BP-10999) and hybridoma #41B1 (FERM BP-11000); wherein said binding of said antibody or antigen binding fragment inhibits osteoclast formation and/or osteoclastic bone resorption; and wherein the abnormal bone metabolism is characterized by insufficient bone growth, mass, or density.